Last reviewed · How we verify
Oral L-ornithine aspartate administration
Oral L-ornithine aspartate administration increases ornithine levels in the body.
Oral L-ornithine aspartate administration increases ornithine levels in the body. Used for Hepatic encephalopathy.
At a glance
| Generic name | Oral L-ornithine aspartate administration |
|---|---|
| Also known as | Oral supplementation with Larnamin (Farmak, Ukraine) |
| Sponsor | Ukrainian Medical Stomatological Academy |
| Drug class | Amino acid supplement |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
L-ornithine aspartate is a combination of the amino acid L-ornithine and aspartic acid. By increasing ornithine levels, it may help to reduce ammonia levels in the blood, which can be beneficial for patients with hepatic encephalopathy.
Approved indications
- Hepatic encephalopathy
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy (PHASE4)
- Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment (NA)
- Supplementation With L-ornithine But Not L-arginine Increases Density of CD68+ and CD163+ Macrophages in Periodontitis (PHASE3)
- Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: